207_Combined course Presentations
Conclusions
No significant differences were seen in efficacy between Cisplatin-Etoposide (CE) and Carboplatin-Paclitaxel (CP)
There was no difference in pneumonitis or esophagitis rates between CE and CP. However, hematologic toxicities and N/V were significantly higher in the CE arm
Both CE and CP with XRT are acceptable standards of care to treat stage III NSCLC, and prospective data is needed to determine the optimum regimen
Made with FlippingBook